Our study here has now shown the ability of SNA structures, particularly HM SNAs, to raise immune responses against antigens (PSA, PSMA, PAP) that are clinically relevant for treating prostate cancer and is consistent with what has been observed with clinically irrelevant model antigens (25). This evidence concerns the gene FOLH1 and Familial prostate cancer.